Rheumatoid arthritis (RA) presents a significant burden to healthcare in the UK. New biological therapies have advanced treatment but at a high cost to the NHS. Certolizumab pegol is a new TNF inhibitor, providing an additional treatment option for RA. In this article Dr Ma and Dr Choy consider the efficacy of certolizumab pegol, and where it may fit into the RA armoury.
No takes yet. Share an insight, caveat, or question.
HY et al. (2009) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: